Yasser Ged1, Ying-Bei Chen2, Andrea Knezevic3, Mark T A Donoghue4, Maria I Carlo1, Chung-Han Lee1, Darren R Feldman1, Sujata Patil3, A Ari Hakimi5, Paul Russo5, Martin H Voss1, Robert J Motzer6. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: Motzerr@mskcc.org.
Abstract
BACKGROUND: Mucinous tubular and spindle-cell carcinoma (MTSCC) is a rare kidney cancer subtype with limited cases reported in the literature. We report on outcomes of 25 patients with this variant who were managed at our institution. MATERIALS AND METHODS: The institution database was queried, and clinical data extracted for patients with MTSCC. Molecular features examined included next-generation sequencing with Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets and allele-specific copy number analysis using the Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing (FACETS) algorithm in a subset of patients. RESULTS: All patients underwent primary tumor-directed therapy (nephrectomy = 23, cryoablation = 2). Metastases were diagnosed in 6 patients (24%), 3 (12%) of whom had de novo metastatic disease. Five of 6 patients with metastatic disease had high-grade histological features compared with 0 of 19 nonmetastatic patients (83% vs. 0%; P < .001, Fisher exact test). Three-year overall survival from diagnosis was 84.8% (95% confidence interval, 59.6-94.9) with a median follow-up time of 3.9 years (range, 1 month to 10.3 years). Three deaths occurred, all from metastatic disease. Four patients received systemic therapy with time to treatment failure ≤6 months across different agents with the exception of 1 patient with prolonged response with sunitinib treatment (30.6 months). The most frequent molecular alterations were neurofibromin 2 mutations (n = 2; 40%), germline alterations (n = 2; 40%) including checkpoint kinase 2 and BRCA2 DNA repair associated mutations, multiple chromosomal copy number losses, and mismatch repair deficiency in 1 patient. CONCLUSION: MTSCC is characterized by localized tumors treated successfully with primary tumor-directed therapy. However, patients with high-grade histological features were more likely to develop metastatic disease with limited responses to standard therapies.
BACKGROUND: Mucinous tubular and spindle-cell carcinoma (MTSCC) is a rare kidney cancer subtype with limited cases reported in the literature. We report on outcomes of 25 patients with this variant who were managed at our institution. MATERIALS AND METHODS: The institution database was queried, and clinical data extracted for patients with MTSCC. Molecular features examined included next-generation sequencing with Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets and allele-specific copy number analysis using the Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing (FACETS) algorithm in a subset of patients. RESULTS: All patients underwent primary tumor-directed therapy (nephrectomy = 23, cryoablation = 2). Metastases were diagnosed in 6 patients (24%), 3 (12%) of whom had de novo metastatic disease. Five of 6 patients with metastatic disease had high-grade histological features compared with 0 of 19 nonmetastatic patients (83% vs. 0%; P < .001, Fisher exact test). Three-year overall survival from diagnosis was 84.8% (95% confidence interval, 59.6-94.9) with a median follow-up time of 3.9 years (range, 1 month to 10.3 years). Three deaths occurred, all from metastatic disease. Four patients received systemic therapy with time to treatment failure ≤6 months across different agents with the exception of 1 patient with prolonged response with sunitinib treatment (30.6 months). The most frequent molecular alterations were neurofibromin 2 mutations (n = 2; 40%), germline alterations (n = 2; 40%) including checkpoint kinase 2 and BRCA2 DNA repair associated mutations, multiple chromosomal copy number losses, and mismatch repair deficiency in 1 patient. CONCLUSION:MTSCC is characterized by localized tumors treated successfully with primary tumor-directed therapy. However, patients with high-grade histological features were more likely to develop metastatic disease with limited responses to standard therapies.
Authors: Steven S Shen; Jae Y Ro; Pheroze Tamboli; Luan D Truong; Qihui Zhai; Soo-Jin Jung; Rita G Tibbs; Nelson G Ordonez; Alberto G Ayala Journal: Ann Diagn Pathol Date: 2007-02 Impact factor: 2.090
Authors: Vadim S Koshkin; Pedro C Barata; Tian Zhang; Daniel J George; Michael B Atkins; William J Kelly; Nicholas J Vogelzang; Sumanta K Pal; JoAnn Hsu; Leonard J Appleman; Moshe C Ornstein; Timothy Gilligan; Petros Grivas; Jorge A Garcia; Brian I Rini Journal: J Immunother Cancer Date: 2018-01-29 Impact factor: 13.751
Authors: Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou Journal: Mod Pathol Date: 2021-03-04 Impact factor: 8.209
Authors: Pedram Argani; Victor E Reuter; John N Eble; Ljiljana Vlatkovic; Oksana Yaskiv; David Swanson; Brendan C Dickson; Cristina R Antonescu; Andres Matoso; Jeffrey Gagan; Doreen N Palsgrove Journal: Am J Surg Pathol Date: 2020-07 Impact factor: 6.298
Authors: Chen Yang; Robert S Cimera; Ruth Aryeequaye; Gowtham Jayakumaran; Judy Sarungbam; Hikmat A Al-Ahmadie; Anuradha Gopalan; S Joseph Sirintrapun; Samson W Fine; Satish K Tickoo; Jonathan I Epstein; Victor E Reuter; Yanming Zhang; Ying-Bei Chen Journal: Mod Pathol Date: 2020-09-02 Impact factor: 7.842